Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Sputum biomarkers of inflammation in cystic fibrosis lung disease.

Sagel SD, Chmiel JF, Konstan MW.

Proc Am Thorac Soc. 2007 Aug 1;4(4):406-17. Review.

2.

Noninvasive biomarkers of airway inflammation in cystic fibrosis.

Sagel SD.

Curr Opin Pulm Med. 2003 Nov;9(6):516-21. Review.

PMID:
14534405
3.

Identifying novel endpoints for cystic fibrosis clinical trials.

Sagel SD.

Adv Pediatr. 2005;52:115-27. Review.

PMID:
16124338
4.

Early intervention in CF: how to monitor the effect.

Weiser G, Kerem E.

Pediatr Pulmonol. 2007 Nov;42(11):1002-7. Review.

PMID:
17893918
5.

Endpoints for clinical trials in young children with cystic fibrosis.

Davis SD, Brody AS, Emond MJ, Brumback LC, Rosenfeld M.

Proc Am Thorac Soc. 2007 Aug 1;4(4):418-30. Review.

6.

Methodological aspects in the analysis of spontaneously produced sputum.

Out TA, Jansen HM, Lutter R.

Monaldi Arch Chest Dis. 2001 Dec;56(6):493-9. Review.

PMID:
11980279
7.

Pulmonary biomarkers in chronic obstructive pulmonary disease.

Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D, Saetta M.

Am J Respir Crit Care Med. 2006 Jul 1;174(1):6-14. Epub 2006 Mar 23. Review.

PMID:
16556692
8.

Markers of airway inflammation in pulmonary diseases assessed by induced sputum.

Dragonieri S, Tongoussouva O, Zanini A, Imperatori A, Spanevello A.

Monaldi Arch Chest Dis. 2009 Sep;71(3):119-26. Review.

PMID:
19999958
9.

The future in paediatric respirology.

Schmidt HJ, Bhandari V, Bhandari A, Davies J, Marshall BC, Praud JP, Zar HJ, Rubin BK.

Respirology. 2010 Jul;15(5):733-41. doi: 10.1111/j.1440-1843.2010.01745.x. Epub 2010 Apr 8. Review. Erratum in: Respirology. 2010 Oct;15(7):1146.

PMID:
20409021
10.

An overview of endpoints for cystic fibrosis clinical trials: one size does not fit all.

Rosenfeld M.

Proc Am Thorac Soc. 2007 Aug 1;4(4):299-301. Review.

PMID:
17652489
11.

Advancing outcome measures for the new era of drug development in cystic fibrosis.

Mayer-Hamblett N, Ramsey BW, Kronmal RA.

Proc Am Thorac Soc. 2007 Aug 1;4(4):370-7. Review.

12.

Pathophysiology and management of pulmonary infections in cystic fibrosis.

Gibson RL, Burns JL, Ramsey BW.

Am J Respir Crit Care Med. 2003 Oct 15;168(8):918-51. Review.

PMID:
14555458
13.

[Examination of exhaled breath condensate in cystic fibrosis].

Fila L, Musil J.

Cas Lek Cesk. 2010;149(4):173-7. Review. Czech.

PMID:
20518250
14.

Monitoring inflammation in CF. Cytokines.

Sagel SD, Accurso FJ.

Clin Rev Allergy Immunol. 2002 Aug;23(1):41-57. Review.

PMID:
12162105
15.

Induced sputum: a window to lung pathology.

Nicholas B, Djukanović R.

Biochem Soc Trans. 2009 Aug;37(Pt 4):868-72. doi: 10.1042/BST0370868. Review.

PMID:
19614609
16.
17.

What's new in CF airway inflammation: an update.

Ratjen F.

Paediatr Respir Rev. 2006;7 Suppl 1:S70-2. Epub 2006 Jun 5. Review.

PMID:
16798601
18.

Pulmonary exacerbations in cystic fibrosis.

Stenbit AE, Flume PA.

Curr Opin Pulm Med. 2011 Nov;17(6):442-7. doi: 10.1097/MCP.0b013e32834b8c04. Review.

PMID:
21881509
19.

Magnetic resonance imaging of cystic fibrosis lung disease.

Wielpütz MO, Eichinger M, Puderbach M.

J Thorac Imaging. 2013 May;28(3):151-9. doi: 10.1097/RTI.0b013e31828d40d4. Review.

PMID:
23545948
20.

Lung clearance index: evidence for use in clinical trials in cystic fibrosis.

Kent L, Reix P, Innes JA, Zielen S, Le Bourgeois M, Braggion C, Lever S, Arets HG, Brownlee K, Bradley JM, Bayfield K, O'Neill K, Savi D, Bilton D, Lindblad A, Davies JC, Sermet I, De Boeck K; European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN) Standardisation Committee.

J Cyst Fibros. 2014 Mar;13(2):123-38. doi: 10.1016/j.jcf.2013.09.005. Epub 2013 Dec 5. Review.

Items per page

Supplemental Content

Write to the Help Desk